ArticleMolecular medicine reports2026
RUVBL1 and CRAF promote periodontal ligament stem cell osteogenic differentiation via the MEK/ERK signaling cascade.
Article in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MAPK signaling is key for osteogenic differentiation of periodontal ligament stem cells (PDLSCs), a process important in treating periodontal injury. RuvB‑like AAA ATPase‑1 (RUVBL1) binds C‑Raf proto‑oncogene serine/threonine‑protein kinase (CRAF) to activate the MAPK signaling pathway, but the specific roles and mechanisms of RUVBL1 and CRAF in PDLSCs remain unclear. In the present study, PDLSCs were subjected to lentiviral transfection for RUVBL1 and CRAF expression manipulation. Flow cytometry was performed to characterize mesenchymal SC (MSC) features. A Cell Counting Kit‑8 assay was used to assess PDLSC proliferative viability. Lipogenic differentiation potential was evaluated using Oil Red O staining following lipogenic induction. Alkaline phosphatase and alizarin red staining were utilized to assess osteogenic differentiation potential and mineralization, respectively, following osteogenic induction. Reverse transcription‑quantitative PCR and western blotting were conducted to determine the effects of RUVBL1 and CRAF on the MAPK signaling pathway in PCLSCs. PDLSCs were determined to be SCs exhibiting self‑renewal and MSC characteristics, including lipogenic and osteogenic differentiation potential. RUVBL1 overexpression enhanced PDLSC osteogenic differentiation while inhibiting proliferative activity and lipogenic differentiation. Conversely, CRAF overexpression promoted PDLSC proliferative activity, as well as osteogenic and lipogenic differentiation. Knockdown of RUVBL1 reduced osteogenic differentiation while enhancing proliferative activity and lipogenic differentiation, whereas knockdown of CRAF suppressed proliferative activity, osteogenic differentiation and lipogenic differentiation. RUVBL1 did not regulate CRAF in PDLSCs. However, overexpression of RUVBL1 or CRAF promoted MEK and ERK phosphorylation, activating the MEK/ERK signaling pathway. Overall, RUVBL1 and CRAF activated the MEK/ERK signaling pathway to promote osteogenic differentiation in PDLSCs, although RUVBL1 did not regulate CRAF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.